Enzyre and Takeda Pharmaceutical have entered into a strategic collaboration to develop assays for the diagnosis and monitoring of congenital bleeding disorders.
In December 2019, Enzyre entered a research collaboration with Takeda Pharmaceutical to develop a device for haemophilia patients to quickly determine their coagulation status at home.
The latest deal builds on the existing agreement while Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
Enzyre CEO Dirk Pollet said: “We have worked closely and successfully with Takeda over the last five years and are very pleased to strengthen our partnership.
“Takeda’s commitment is a validation of our groundbreaking technology and reflects our combined goal to drive the standard of care forward for patients, tackling bleeding disorders, enabling an improved quality of life.”
Leveraging Enzyre’s Enzypad platform technology, the Hemophilia Enzycard can be used to check the coagulation status of haemophilia patients.
Individuals with haemophilia do not have enough blood-clotting proteins such as factor VIII (FVIII), which causes them to bleed for a longer time after an injury versus those without haemophilia.
Enzycard will help patients to carry out the test in a home setting and transfer coagulation status results to the physician through a mobile phone app instantly.
It will facilitate timely personalised therapy adjustments that could enhance patient outcomes without needing to travel and hospital exposure, reducing treatment burden and cost.
Takeda Innovative Patient Solutions global commercial lead Chris Easton said: “Technologies like Enzyre’s Enzypad platform support Takeda’s ambition to deliver personalised care and address the unique needs of every single patient.
“We are excited to continue working together with Enzyre to realise our common goal of advancing the standard of care and optimising treatment outcomes for patients with bleeding disorders.”